Publication Date
| In 2025 | 0 |
| Since 2024 | 1 |
| Since 2021 (last 5 years) | 1 |
Descriptor
| Autism Spectrum Disorders | 1 |
| Children | 1 |
| Drug Therapy | 1 |
| Epilepsy | 1 |
| Foreign Countries | 1 |
| Health Care Costs | 1 |
| Pharmacology | 1 |
Source
| Journal of Autism and… | 1 |
Author
| Aine Roddy | 1 |
| Bethany Oakley | 1 |
| Celso Arango | 1 |
| Declan Murphy | 1 |
| James Cusack | 1 |
| Maria Andreina Mendez | 1 |
| Martin Knapp | 1 |
| Michela Tinelli M | 1 |
| Roberto Canitano | 1 |
| Vinciane Quoidbach | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
| Ireland | 1 |
| Italy | 1 |
| Spain | 1 |
| United Kingdom (England) | 1 |
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkMichela Tinelli M; Aine Roddy; Martin Knapp; Celso Arango; Maria Andreina Mendez; James Cusack; Declan Murphy; Roberto Canitano; Bethany Oakley; Vinciane Quoidbach – Journal of Autism and Developmental Disorders, 2024
We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children's families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For…
Descriptors: Foreign Countries, Autism Spectrum Disorders, Epilepsy, Pharmacology
